References
- Campbell CI, Weisner C, LeResche L, et al. Age and gender trends in long-term opioid analgesic use for noncancer pain. Am J Public Health 2010;100:2541-7
- White AG, Birnbaum HG, Mareva MN, et al. Direct costs of opioid abuse in an insured population in the United States. J Manag Care Pharm 2005;11:469-79
- White AG, Birnbaum HG, Rothman DB, et al. Development of a budget-impact model to quantify potential cost savings from prescription opioids designed to deter abuse or ease of extraction. Appl Health Econ Health Policy 2009;7:61-70
- Birnbaum HG, White AG, Reynolds JL, et al. Estimated costs of prescription opioid analgesic abuse in the United States in 2001: a societal perspective. Clin J Pain 2006;22:667-76
- Ruetsch C. Empirical view of opioid dependence. J Manag Care Pharm 2010;16(1):S9-S13
- Strassels SA. Economic burden of prescription opioid misuse and abuse. J Manag Care Pharm 2009;15:556-62
- Boswell K, Kwong WJ, Kavanagh S. Burden of opioid-associated gastrointestinal side effects from clinical and economic perspectives: a systematic literature review. J Opioid Manag 2010;6:269-89. Review
- Kwong WJ, Diels J, Kavanagh S. Costs of gastrointestinal events after outpatient opioid treatment for non-cancer pain. Ann Pharmacother 2010;44:630-40. Epub 2 March 2010
- Hass B, Lungershausen J, Hertel N, et al. Cost-effectiveness of strong opioids focussing on the long-term effects of opioid-related fractures: a model approach. Eur J Health Econ 2009;10:309-021. Epub 21 December 2008
- Zorba Paster R. Chronic pain management issues in the primary care setting and the utility of long-acting opioids. Expert Opin Pharmacother 2010;11:1823-33. Review
- Katz N, Rauck R, Ahdieh H, et al. A 12-weeks, randomized, placebo-controlled trial assessing the safety and efficacy of oxymorphone extended release for opioid-naïve patients with chronic low back pain. Curr Med Res Opin 2007;23:117-28
- Hale ME, Fleischmann R, Salzman R, et al. Efficacy and safety of controlled-release versus immediate-release oxycodone: randomized, double-blind evaluation in patients with chronic back pain. Clin J Pain 1999;15:179-83
- Hale ME, Dvergsten C, Gimbel J. Efficacy and safety of oxymorphone extended release in chronic low back pain: results of a randomized, double-blind, placebo- and active-controlled phase III study. J Pain 2005;6:21-8
- Holmquist GL. Opioid metabolism and effects of cytochrome P450. Pain Med 2009;10(Suppl 1):S29
- Smith HS. Opioid metabolism. Mayo Clin Proc 2009;84:613-24
- Berner T, Thomson H, Hartry A, et al. A Comparison of daily average consumption of oxycodone controlled release (OxyContin CR) and oxymorphone extended release (Opana ER) in patients with low back pain. P&T Journal 2011;36:139-44
- Rubino M, Summers KH, Puenpatom A, et al. A comparison of daily average consumption (DACON) of oxycodone and oxymorphone long-acting oral tablets. J Manag Care Pharm 2011;17:367-76
- Frost and Sullivan. U.S Opioid Pain Management Market, San Antonio, July 2010
- Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-83
- Romano PS, Roos LL, Jollis J. Adapting a clinical comorbidity index for use with ICD-9-CM administrative data. J Clin Epidemiol 1993;46:1075-9
- Paice JA. Chronic treatment-related pain in cancer survivors. Pain 2011;152(Suppl 3):84-9. Epub 30 October 2010
- Summers KH, Puenpatom RA, Rajan N, et al. Economic impact of potential drug-drug interactions in opioid analgesics. J Med Econ 2011;14:390-6. Epub 17 May 2011